BASILEA: DEVELOPING NEW MEDICINES AGAINST RESISTANT INFECTIONS

By bringing its full team under one roof at Switzerland Innovation Park Basel Area - Main Campus, the company created a workplace designed around its people, its science and its mission to help patients.

«Switzerland Innovation Park Basel Area – Main Campus fulfills all the criteria I need to run a biotech company. The talent is here, the environment is here and the ecosystem is here to support that.»

David Veitch

CEO, Basilea

Serious bacterial and fungal infections remain a major medical challenge: existing treatments fall short, and resistance keeps building up. “There is a need for new drugs in this area, and that’s what Basilea aims to do,” says David Veitch, CEO of Basilea. Founded in 2000, the commercial-stage biopharmaceutical company has about 200 employees. Its antifungal Cresemba is approved in more than 70 countries to treat invasive mold infections, and its antibiotic Zevtera treats severe bacterial infections such as hospital-acquired pneumonia. Developing such medicines takes a whole company. “Turning science into a drug is a real multifunctional effort,” says Veitch. Yet until 2022, Basilea’s teams were split across two sites in the center of Basel.

That year, Basilea brought everyone together at the Main Campus of Switzerland Innovation Park Basel Area in Allschwil, on the western edge of the city. The company was able to design much of its new space itself: labs and offices, open-plan areas for close collaboration, communal spaces and quieter zones. R&D and other functions now sit close enough to connect naturally, while each keeps the focus of its own dedicated space. Veitch calls the move “a seminal moment in the evolution of Basilea.”

The effect on daily work is clear. “Communication and collaboration significantly improved compared to what we had before,” says Veitch. Beyond its own walls, Basilea is part of a wider campus community of startups, scaleups, established companies, academic groups and research institutes. Many connections start informally, in a conversation at lunch or at a campus event. “The informal ability to network with people in the life sciences industry is something Basilea employees really value,” Veitch adds.

For Veitch, the space is ultimately about the people in it and the purpose that drives them: “Powering innovation at Basilea is really about people. What gets people up in the morning is bringing out new drugs that benefit patients.”

Caption: David Veitch, CEO, Basilea © up&up, Zürich

Key Facts

  • 0

    Founded

  • 0

    Employees

  • 0

    Move to Main Campus in Allschwil

Please accept marketing cookies to watch this video.

Explore More Success Stories